|
The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and Thursday and not separately reported by Alliance News: ---------- Canal+ SA - Paris-based media and telecommunications conglomerate - Says its VAT rate dispute with the French tax authorities has been resolved. VAT applies at a reduced rate on television subscription services. Canal+ says the agreement follows clarifications published by the tax authorities in September, and work jointly carried out on the definition and operational terms of catch-up television at Canal+. Company says it will not make any additional provision in its accounts, as future related tax audits for subsequent years should not result in any significant additional adjustments. It has committed a total of €363 million for associated payments. Previously, on Thursday, Canal+ announces that as part of its refinancing strategy, it has successfully signed a €1.80 billion financing split between a €500 million 12-month term loan, extendable up to 24 months, and an €1.30 billion five-year term loan ‘on attractive terms’. Says the transaction was significantly oversubscribed by a syndicate of leading international banks, reflecting strong market confidence. Adds that it represents the final step in the refinancing of the debt related to its acquisition of MultiChoice, and contributes to the progressive extension and diversification of the group’s debt maturity profile. ---------- Ananda Pharma PLC - London-based developer of cannabidiol medicines to treat chronic conditions - Welcomes US President Donald Trump’s executive order to reschedule cannabis from Schedule 1 to Schedule 3 under the Controlled Substances Act. Says this will enhance Ananda’s access to institutional capital from entities which cannot invest in companies which handle Schedule 1 drugs, but which are able to invest in Schedule 3 drug development companies. It will also enable accelerated clinical trials of MRX1 in the US and ease the regulatory pathway, as well simplifying transportation of MRX1 to and within the US for trials. Says the move ‘is a common sense and tangible recognition of the potential medical benefits of cannabis and CBD and strengthens Ananda’s position at the forefront of CBD clinical research and development.’ ---------- ProService Building Services Marketplace PLC - equipment hire company - Reports results for the six months ended September 30. Notes that these are based on its under its former name of HSS Hire before the completion of the commercial agreement with Speedy Hire in November, the equity investment by Speedy Hire in ProService, and the disposal of The Hire Service Co. Revenue decreases 14% on-year to £135.6 million from £157.4 million. Pretax loss widens to £6.2 million from £3.1 million. ProService says trading conditions remain challenging, with a weak commercial environment impacting performance. It now expects full-year revenue of approximately £260 million with ‘around break even’ underlying earnings before interest, tax, depreciation and amortisation, which for the half year fell to £14.2 million from £23.3 million. Says financial 2027 should be a transitional year, with results in line with market expectations. ---------- Plexus Holdings PLC - gas, oil and renewable energy projects focused on the UK & Netherlands - Reports final results for the year ended June 30. Pretax loss is £3.3 million, flipped from a £2.8 million profit for the prior year. Sales revenue falls to £4.5 million from £12.7 million. Plexus notes that its financial 2024 results were ‘materially influenced by a one-off exceptional licence deal, which elevated both revenue and profit for that period.’ Non-Executive Chair Ben van Bilderbeek says the latest year’s results reflect Plexus’ planned investment phase as it rebuilds and expands rental operations. He adds: ‘Looking ahead, despite ongoing challenges in sentiment towards offshore oil and gas, we remain highly optimistic.’ ---------- Fusion Antibodies PLC - Belfast-based contract researcher that provides discovery, design and optimisation services for therapeutic antibodies - Says the US’ National Cancer Institute has expressed an interest in continuing to use OptiMAL as a frontline human antibody discovery platform for a range of targets, following their joint validation project between late 2023 and early 2025. NCI has provided a proposal to extend the 2023 collaboration agreement to allow screening of several named targets. Fusion expects negotiations to continue into early 2026. Adds that formal approval processes at the US National Institutes of Health are likely to take several further months to complete, and that there is no guarantee that an extension will be reached. ---------- Thruvision Group PLC - Abingdon, England-based provider of walkthrough people-screening technology - Receives further order in the US retail distribution market. Says it has expanded its partnership with a Germany-based athletic apparel and footwear manufacturer with an additional WalkTHRU deployment at a new site in the US, bringing this client’s total number of WalkTHRU lanes to four. Thruvision also confirms that an order announced on December 8, for its SpotCHECK people-screening solution for aviation worker screening, was received by Seattle-Tacoma International Airport as expected. ---------- Revel Collective PLC - bar operator - Says it is in talks with ‘a number of credible parties’, but warns that any deal is unlikely to return value to shareholders. Revel has ‘engaged with a significant number of potential acquirers of the businesses it operates’. ‘Negotiations are ongoing, with the continuing support of the group’s bank, however, there can be no certainty on the timing of any transactions. Furthermore, there can be no guarantee that these negotiations will result in any transactions,’ Revel adds. Says it considered an equity fundraise, but does not have ‘the necessary support’ for one. Annual results for the year that ended June 28 will not be published by December 28, Revel adds, so trading of its shares will be suspended before the end of the year. ---------- Fletcher King PLC - London-based chartered surveyors firm - Reports results for the six months ended October 31. Turnover rises slightly on an annual basis but remains broadly flat at £1.6 million. Pretax earnings decrease to £1,000 from £85,000. ‘A quiet period for property transactions has been compensated for by an increase in non-transactional revenue,’ the company says. Declares no interim dividend, unchanged annually. Looking ahead, Fletcher Kind says the outlook for the rest of the year ending April 30 is more encouraging, and that it hopes for better progress in closing some of the transactions in its pipeline. ---------- Kodal Minerals PLC - West Africa-focused mineral explorer and developer - Remains non-revenue generating, the same as the prior year, for the six months ended September 30. Pretax loss narrows to £355,019 from £1.5 million. Company records one-off £217,751 share of profit of an associate, against a £831,819 loss the year before. Kodal says mining activities continued at the start of the period, at the Bougouni Lithium Project, with an average grade of 1.17% lithium oxide, followed by an expected pause during the wet season from July to September. Says approximately 45,000 tonnes of lithium spodumene product, grading an average lithium oxide content of 5.39%, was produced on site during the half year. Non-Executive Chair Robert Wooldridge notes that ‘market sentiment remains cautious due to fluctuating battery demand forecasts, high inventories in parts of the supply chain, and the ongoing uncertainty surrounding global trade policy.’ Adds, however: ‘Despite the risk of near-term pressures, long-term prospects remain robust, supported by energy transition commitments and advances in battery technology.’ ---------- abrdn Diversified Income & Growth PLC - Edinburgh-based investor across asset classes - Reports net asset value per share of 50.36 pence as of September 30, down 25% from 67.48p one year prior. Total return is minus 26.4% for the six months ended September 30. Half-year report follows the company’s announcement on Thursday that abrdn Diversified, which is in the process of a managed wind-down, either has completed or expects to complete shortly the sales of four more of its fund investments and private market assets. Raises approximately £3.4 million in gross consideration, and unlocks around £700,000 of cash being retained in respect of its undrawn commitments. abrdn Diversified says it remains committed to returning the net proceeds of any realisations to shareholders progressively in an efficient and fair manner, and currently expects to complete multiple further secondary sales of remaining fund interests ‘in the coming month’. Adds that it remains on track to put forward proposals for a members’ voluntary liquidation in the first quarter of 2026. ---------- EDX Medical Group PLC - Cambridge, England-based developer of digital diagnostic products and services - Reports results for the six months ended September 30. Pretax loss widens on-year to £2.3 million from £1.7 million. Revenue increases to £173,045 from £17,811, but administrative expenses increase to £2.2 million from £1.7 million, ‘reflecting additional investment in [the company’s] operations, particularly in cancer diagnostics.’ Looking ahead, EDX says it ‘is confident its dual ’commercial and development’ strategy and the quality of diagnostic products will serve it well in a fast-growing global market and the board is grateful for the support of both institutional and individual investors who continue to support the company financially.’ Also, on Thursday, EDX announces the UK commercial launch of its BC95 testing service ‘that improves the early detection of bowel cancer.’ It will be available ‘within the next few weeks’, including ‘a suite of diagnostic tests, that can be selected for individual patient needs.’ ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
